Literature DB >> 25854905

The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B.

Enver Yüksel1, Erdem Akbal2, Erdem Koçak3, Ömer Akyürek4, Seyfettin Köklü5, Fuat Ekiz6, Barış Yılmaz6.   

Abstract

Chronic viral hepatitis B (CHB) is an important cause of morbidity and mortality. Adipokine stimulation might play an important role in the pathogenesis of chronic inflammation. The aim of this study was to evaluate serum visfatin concentrations and the relationship between visfatin, fibrosis, liver inflammation, and acute phase reactants in CHB patients.The sampling universe of the study consisted of 41 CHB patients and 25 healthy controls. All patients had positive hepatitis B surface antigen (Hepatitis e antigen (HBeAg) positive n: 7, n: 34 HBeAg negative) for at least 6 months and detectable serum HBV DNA. Serum visfatin concentrations were significantly higher in the CHB patients [18.0 ± 10.9 ng dL(-1)] than in the healthy controls [9.4 ± 1.6 ng dL(-1)] [P < 0.001]. On the other hand, fibrinogen and haptoglobin concentrations were significantly lower in CHB patients. A strong negative correlation was observed between serum visfatin concentration, haptoglobin, and fibrinogen levels; however, there was no significant correlation between visfatin, glucose, alanine aminotransferase, aspartate aminotransferase, BMI, Knodell score, fibrosis score, hepatitis B virus DNA, sedimentation, and C-reactive protein. Visfatin concentrations were elevated and visfatin was negatively correlated with haptoglobin and fibrinogen levels in CHB patients.

Entities:  

Keywords:  Chronic hepatitis B; Fibrinogen; Haptoglobin; Visfatin

Mesh:

Substances:

Year:  2015        PMID: 25854905     DOI: 10.1007/s00508-015-0723-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  27 in total

1.  Plasma resistin concentration, and steatosis and insulin sensitivity in hepatitis C virus-infected patients.

Authors:  Jean Michel Petit; Anne Minello; Catherine Brisard; Francoise Galland; Laurence Duvillard; Bruno Verges; Patrick Hillon
Journal:  J Gastroenterol Hepatol       Date:  2006-03       Impact factor: 4.029

Review 2.  What's new in our understanding of the role of adipokines in rheumatic diseases?

Authors:  Rodolfo Gómez; Javier Conde; Morena Scotece; Juan Jesus Gómez-Reino; Francisca Lago; Oreste Gualillo
Journal:  Nat Rev Rheumatol       Date:  2011-08-02       Impact factor: 20.543

Review 3.  Cytokines, STATs and liver disease.

Authors:  Bin Gao
Journal:  Cell Mol Immunol       Date:  2005-04       Impact factor: 11.530

4.  Visfatin levels in nonalcoholic fatty liver disease.

Authors:  Erdem Akbal; Erdem Koçak; Adnan Taş; Enver Yüksel; Seyfettin Köklü
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

5.  Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C.

Authors:  Ancha Baranova; Mohammed H Jarrar; Maria Stepanova; Andrew Johnson; Nila Rafiq; Terry Gramlich; Vikas Chandhoke; Zobair M Younossi
Journal:  Digestion       Date:  2010-09-15       Impact factor: 3.216

6.  Comparative study of C-reactive protein in chronic hepatitis B and chronic hepatitis C.

Authors:  M Shima; K Nakao; Y Kato; K Nakata; N Ishii; S Nagataki
Journal:  Tohoku J Exp Med       Date:  1996-03       Impact factor: 1.848

7.  Serum adiponectin in chronic hepatitis C and B.

Authors:  D Siagris; G Vafiadis; M Michalaki; A Lekkou; I Starakis; M Makri; V Margaritis; M Christofidou; A C Tsamandas; C Labropoulou-Karatza
Journal:  J Viral Hepat       Date:  2007-08       Impact factor: 3.728

8.  Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.

Authors:  Su-Ryun Kim; Yun-Hee Bae; Soo-Kyung Bae; Kyu-Sil Choi; Kwon-Ha Yoon; Tae Hyeon Koo; Hye-Ock Jang; Il Yun; Kyu-Won Kim; Young-Guen Kwon; Mi-Ae Yoo; Moon-Kyoung Bae
Journal:  Biochim Biophys Acta       Date:  2008-01-16

Review 9.  Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity.

Authors:  Tracy Luk; Zeenat Malam; John C Marshall
Journal:  J Leukoc Biol       Date:  2008-02-05       Impact factor: 4.962

10.  Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease.

Authors:  R Aller; D A de Luis; O Izaola; M Gonzalez Sagrado; R Conde; M C Velasco; T Alvarez; D Pacheco; J M González
Journal:  Dig Dis Sci       Date:  2008-11-14       Impact factor: 3.199

View more
  2 in total

1.  Serum Visfatin Levels in Ulcerative Colitis.

Authors:  Serkan Dogan; Kadri Guven; Mehmet Celikbilek; Kemal Deniz; Berkay Saraymen; Sebnem Gursoy
Journal:  J Clin Lab Anal       Date:  2015-12-14       Impact factor: 2.352

Review 2.  Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression.

Authors:  Ming-Ling Chang; Zinger Yang; Sien-Sing Yang
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.